Lexicon Pharmaceuticals, Inc. — Q2 2013 Form 10-Q
Reporting period: Three and six months ended June 30, 2013. Lexicon is a biopharmaceutical company developing drug candidates and relies mainly on collaborations and licenses for revenue. Amounts below are in U.S. dollars; financial statement amounts are generally in millions unless noted.
Financial performance and liquidity
| Metric | Q2 2013 | Q2 2012 | Six months 2013 | Six months 2012 |
|---|---|---|---|---|
| Revenue | $0.214 | $0.199 | $0.574 | $0.499 |
| Research and development | $23.692 | $19.355 | $44.019 | $42.392 |
| General and administrative | $4.669 | $4.162 | $8.993 | $8.727 |
| Operating loss | $(28.624) | $(25.480) | $(54.179) | $(54.863) |
| Net loss | $(29.080) | $(25.931) | $(55.054) | $(55.799) |
| Net loss per share | $(0.06) | $(0.05) | $(0.11) | $(0.12) |
- Six-month operating cash use was $45.4 million, versus $49.0 million in 2012. Investing activities provided $39.5 million, principally from net investment maturities; financing activities used $1.3 million. Cash and cash equivalents fell $7.2 million during the half.
- At June 30, cash, cash equivalents and short-term investments totaled $175.4 million, down from $223.2 million at December 31, 2012. Current assets were $183.1 million and current liabilities $40.9 million.
- Total liabilities were $108.3 million; equity was $215.1 million. The $22.7 million mortgage balance was classified as current, with a $21.4 million balloon payment due in April 2014. The loan bears fixed interest of 8.23%.
- Accumulated deficit was $954.9 million. The filing reports no product-level or gross-margin figures; revenue was minimal relative to operating expenses.
Material changes and unusual items
- Q2 revenue increased 8% year over year; first-half revenue increased 15%. Collaborative research revenue rose 41% for the half, primarily from the Taconic Farms alliance, while subscription and license fees fell 47%.
- R&D expense rose 22% in Q2 and 4% for the half. Management attributed the increases mainly to external preclinical and clinical research costs. First-half G&A expense increased 3%.
- Q2 net loss widened from $25.9 million to $29.1 million, while the first-half loss narrowed from $55.8 million to $55.1 million. The first-half increase in the fair value of the Symphony Icon purchase liability was $1.7 million, compared with $4.2 million in 2012.
- During the first half, performance-based restricted stock units tied to dosing the first patient in a pivotal human clinical trial vested. Stock-based compensation expense totaled $4.0 million for the half.
Outlook, risks and contingencies
- Management said available unrestricted cash and investments, together with expected collaboration, license and other receipts, should fund operations for at least 12 months. It expects substantial R&D spending and continued losses; additional financing may be needed thereafter and may be unavailable or dilutive.
- Revenue depends on collaborations, licensing, milestone achievement and potential royalties; the company noted that it relies on a limited number of revenue sources and that results may fluctuate.
- Symphony Icon arrangements may require contingent payments of up to $45 million, generally tied to licensing proceeds or specified U.S. regulatory approval circumstances.
- The Texas Enterprise Fund award carries job-creation commitments. Failure to meet them could result in repayment; maximum aggregate exposure is approximately $14.2 million before applicable credits, including $302,000 in 2013.
- The company reported ordinary-course legal proceedings that it did not expect to have a material adverse effect. Key stated risks include clinical and regulatory uncertainty, dependence on collaborators and third parties, need for financing, intellectual-property disputes, commercialization and reimbursement challenges, and stock-price volatility.
- Management reported disclosure controls and procedures were effective and no significant subsequent changes in internal controls.
Important facts for investors to verify
- Whether cash use and collaboration or licensing receipts support management’s stated minimum 12-month funding runway.
- How Lexicon plans to address the $21.4 million mortgage balloon due in April 2014.
- Progress and potential financial implications of clinical programs, including the pivotal-trial milestone associated with performance-based awards.
- Potential Symphony Icon contingent payments and Texas job-creation obligations, including credits that may reduce exposure.
- Changes in R&D spending, collaboration revenue concentration, and the availability and terms of any future financing.